Bio Spectrum Magazine - August 2017Add to Favorites

Bio Spectrum Magazine - August 2017Add to Favorites

Go Unlimited with Magzter GOLD

Read Bio Spectrum along with 8,500+ other magazines & newspapers with just one subscription  View catalog

1 Month $9.99

1 Year$99.99 $49.99

$4/month

Save 50% Hurry, Offer Ends in 3 Days
(OR)

Subscribe only to Bio Spectrum

1 Year$11.88 $7.99

Save 33% Easter Sale!. ends on April 1, 2024

Buy this issue $0.99

Gift Bio Spectrum

7-Day No Questions Asked Refund7-Day No Questions
Asked Refund Policy

 ⓘ

Digital Subscription.Instant Access.

Digital Subscription
Instant Access

Verified Secure Payment

Verified Secure
Payment

In this issue

Shortage In Europe of Oncology Drugs... An opportunity for Indian Pharma?
Indian drug companies are facing strong headwinds due to prompt regulatory action of United States Food and Drug Administration (USFDA), likely imposition of Border Adjustment Tax (BAT) and delay in new drug approvals. Probably, it is the best time for Indian pharma companies to explore opportunities and business in the European market.

Shortage In Europe Of Oncology Drugs... An Opportunity For Indian Pharma?

Indian drug companies are facing strong headwinds due to prompt regulatory action of United States Food and Drug Administration (USFDA), likely imposition of Border Adjustment Tax (BAT) and delay in new drug approvals. Probably, it is the best time for Indian pharma companies to  explore opportunities and business in the European market.

Shortage In Europe Of Oncology Drugs... An Opportunity For Indian Pharma?

8 mins

US FDA Warning Letters And Indian Pharma

Greater emphasis on quality will allow India to participate more fully in existing global venues such as the International Council for Harmonisation (ICH) and the Pharmaceutical Inspection Cooperation Scheme (PIC/S) – which will enable stronger collaboration and synergies among regulators. Quality is good for economic development, the market, and most importantly, patients and consumers everywhere.

US FDA Warning Letters And Indian Pharma

9 mins

Industry Needs To Work Closely With Indian Govt For Smooth Implementation Of GST

The new tax regime will contribute significantly towards every sector of economic growth, broad export expansion and without saying ample job opportunities. GST is collaborative approach and much awaited tax reform and it is a one more welcome step to move ahead towards more globalization. The roll out will yield many positive benefits but Companies will need to make major changes in their process.

Industry Needs To Work Closely With Indian Govt For Smooth Implementation Of GST

7 mins

India Free From Avian Influenza

Strict surveillance including culling, disinfection and clean-up have worked remarkably in making India free from Avian Influenza. Specified actions formulated by the Ministry of Health still needs to be taken up regularly.

India Free From Avian Influenza

4 mins

Growing Burden Of Head And Neck Cancer In India

Despite great advancements, the management of Head and Neck cancers still remains a problematic and intriguing issue due to the complex anatomy of the various sites.

Growing Burden Of Head And Neck Cancer In India

3 mins

Industry - Academia Collaboration For The Early Development Of Biopharmaceuticals

With an aim of creating a globally competitive biopharmaceutical industry that addresses the country’s major concerns around barriers to affordable healthcare, Innovate in India (I3) program was launched by Dr Harsh Vardhan, Union Minister of Science & Technology on 30th June 2017 in New Delhi.

Industry - Academia Collaboration For The Early Development Of Biopharmaceuticals

2 mins

Read all stories from Bio Spectrum

Bio Spectrum Magazine Description:

PublisherMM Activ Sci-Tech Communication

CategoryBusiness

LanguageEnglish

FrequencyMonthly

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

  • cancel anytimeCancel Anytime [ No Commitments ]
  • digital onlyDigital Only
MAGZTER IN THE PRESS:View All